Zeynep Cakir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zeynep Cakir has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Hacimuftuoglu
Department of Medical Pharmacology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
1 shared publication - Ali Taghizadehghalehjoughi
Faculty of Medicine, Department of Medical Pharmacology, Bilecik Seyh Edebali University, Bilecik, Turkey
1 shared publication - Anca Oana Docea
Department of Toxicology, University of Medicine and Pharmacy of Craiova, Craiova, Romania
1 shared publication - Aristidis Tsatsakis
Center of Toxicology & Science Applications, Medical School, University of Crete, 71003 Heraklion, Greece
1 shared publication - Daniela Calina
Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
1 shared publication - Serkan Yildirim
Faculty of Veterinary, Department of Pathology, Ataturk University, Erzurum, Turkey
1 shared publication
Latest Publications
- Open Access
- 9 February 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (2) , 246
A Selective Histamine H4 Receptor Antagonist, JNJ7777120, Role on glutamate Transporter Activity in Chronic Depression
Glutamate release and reuptake play a key role in the pathophysiology of depression. glutamatergic nerves in the hippocampus region are modulated by histaminergic afferents. Excessive accumulation of glutamate in the synaptic area causes degeneration of neuron cells. The H4 receptor is defined as the main immune system histamine receptor with a pro-inflammatory role. To understand the role of this receptor, the drug JNJ7777120 was used to reveal the chronic depression-glutamate relationship. We have important findings showing that the H4 antagonist increases the glutamate transporters’ instantaneous activity. In our experiment, it has been shown that blocking the H4 receptor leads to increased neuron cell viability and improvement in behavioral ability due to glutamate. Therefore, JNJ can be used to prevent neurotoxicity, inhibit membrane phospholipase activation and free radical formation, and minimize membrane disruption. In line with our findings, results have been obtained that indicate that JNJ will contribute to the effective prevention and treatment of depression.
- 9 February 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (2) , 246
Open AccessA Selective Histamine H4 Receptor Antagonist, JNJ7777120, Role on glutamate Transporter Activity in Chronic Depression
Glutamate release and reuptake play a key role in the pathophysiology of depression. glutamatergic nerves in the hippocampus region are modulated by histaminergic afferents. Excessive accumulation of glutamate in the synaptic area causes degeneration of neuron cells. The H4 receptor is defined as the main immune system histamine receptor with a pro-inflammatory role. To understand the role of this receptor, the drug JNJ7777120 was used to reveal the chronic depression-glutamate relationship. We have important findings showing that the H4 antagonist increases the glutamate transporters’ instantaneous activity. In our experiment, it has been shown that blocking the H4 receptor leads to increased neuron cell viability and improvement in behavioral ability due to glutamate. Therefore, JNJ can be used to prevent neurotoxicity, inhibit membrane phospholipase activation and free radical formation, and minimize membrane disruption. In line with our findings, results have been obtained that indicate that JNJ will contribute to the effective prevention and treatment of depression.